Abstract
Antisynthetase syndrome encompassing a symptom complex with severe interstitial lung disease is the severest subtype of polymyositis and dermatomyositis. The characteristic feature of antisynthetase syndrome is the insufficient efficiency of traditional therapy with glucocorticosteroids and cytostatics, which determines the prognosis of the disease and the need for new therapeutic approaches to treating these patients.
MeSH terms
-
Antibodies, Monoclonal, Murine-Derived* / administration & dosage
-
Antibodies, Monoclonal, Murine-Derived* / adverse effects
-
Antibodies, Monoclonal, Murine-Derived* / immunology
-
Antigens, CD20 / analysis
-
Cell- and Tissue-Based Therapy / methods
-
Dermatomyositis / complications*
-
Dermatomyositis / immunology
-
Drug Monitoring
-
Humans
-
Immunologic Factors / administration & dosage
-
Immunologic Factors / adverse effects
-
Immunologic Factors / immunology
-
Lung Diseases, Interstitial / etiology
-
Lung Diseases, Interstitial / physiopathology
-
Monitoring, Immunologic
-
Myositis* / etiology
-
Myositis* / immunology
-
Myositis* / physiopathology
-
Myositis* / therapy
-
Randomized Controlled Trials as Topic
-
Rituximab
-
Treatment Outcome
Substances
-
Antibodies, Monoclonal, Murine-Derived
-
Antigens, CD20
-
Immunologic Factors
-
Rituximab